Cargando…

Natalizumab treatment reduces microglial activation in the white matter of the MS brain

OBJECTIVE: To evaluate whether natalizumab treatment reduces microglial activation in MS. METHODS: We measured microglial activation using the 18-kDa translocator protein (TSPO)-binding radioligand [(11)C]PK11195 and PET imaging in 10 patients with MS before and after 1 year treatment with natalizum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sucksdorff, Marcus, Tuisku, Jouni, Matilainen, Markus, Vuorimaa, Anna, Smith, Sarah, Keitilä, Joonas, Rokka, Johanna, Parkkola, Riitta, Nylund, Marjo, Rinne, Juha, Rissanen, Eero, Airas, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624093/ https://www.ncbi.nlm.nih.gov/pubmed/31355310 http://dx.doi.org/10.1212/NXI.0000000000000574

Ejemplares similares

Microglial activation, white matter tract damage, and disability in MS
por: Rissanen, Eero, et al.
Publicado: (2018)

Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
por: Sucksdorff, Marcus, et al.
Publicado: (2020)

Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging
por: Bezukladova, Svetlana, et al.
Publicado: (2020)

High serum neurofilament associates with diffuse white matter damage in MS
por: Saraste, Maija, et al.
Publicado: (2020)

Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET
por: Nylund, Marjo, et al.
Publicado: (2021)

Adenosine A(2A) receptor availability in patients with early- and moderate-stage Parkinson’s disease
por: Waggan, Imran, et al.
Publicado: (2022)

Innate Immune Cell–Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis
por: Misin, Olavi, et al.
Publicado: (2022)

Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography
por: Airas, Laura, et al.
Publicado: (2018)

TSPO-Detectable Chronic Active Lesions Predict Disease Progression in Multiple Sclerosis
por: Polvinen, Eero, et al.
Publicado: (2023)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease
por: Vuorimaa, Anna, et al.
Publicado: (2017)

Imaging neuroinflammation in multiple sclerosis using TSPO-PET
por: Airas, Laura, et al.
Publicado: (2015)

Exposure to natalizumab during pregnancy and lactation is safe – No
por: Airas, Laura
Publicado: (2020)

Cognitive Effects of White Matter Pathology in Normal and Pathological Aging
por: Kaskikallio, Alar, et al.
Publicado: (2019)

Differences in brain changes between adults with childhood‐onset epilepsy and controls: A prospective population‐based study
por: Sillanpää, Matti, et al.
Publicado: (2021)

Effects of White Matter Hyperintensities on Verbal Fluency in Healthy Older Adults and MCI/AD
por: Kaskikallio, Alar, et al.
Publicado: (2021)

Association of neuroinflammation with episodic memory: a [(11)C]PBR28 PET study in cognitively discordant twin pairs
por: Lindgren, Noora, et al.
Publicado: (2020)

White Matter Changes on Diffusion Tensor Imaging in the FINGER Randomized Controlled Trial
por: Stephen, Ruth, et al.
Publicado: (2020)

Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells
por: Saraste, Maija, et al.
Publicado: (2016)

Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise
por: Matheson, Granville James, et al.
Publicado: (2019)

Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly
por: Ekblad, Laura L, et al.
Publicado: (2023)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly
por: Snellman, Anniina, et al.
Publicado: (2023)

Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson’s disease
por: Ellfolk, Ulla, et al.
Publicado: (2013)

Regional gray matter correlates of memory for emotion-laden words in middle-aged and older adults: A voxel-based morphometry study
por: Saarela, Carina, et al.
Publicado: (2017)

ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease – Study Protocol and Baseline Characteristics
por: Snellman, Anniina, et al.
Publicado: (2022)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Brain white matter hyperintensities in Kawasaki disease: A case–control study
por: Laukka, Dan, et al.
Publicado: (2022)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_34coram6ajlnv89dab3657asdj